Name: Relmada Therapeutics, Inc. (RLMD) Financial Statements
Creator: FinSpry

Relmada Therapeutics Income Statement Analysis

Revenue, earnings, and profit margins in millions USD

Scale:

Scroll to see more

Relmada Therapeutics, Inc. income statement - Annual data in millions USD
Breakdown	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Revenue & Gross Profit
Revenue	0.00	0.00	0.00	0.00	0.00
Cost of Revenue	0.00	0.00	0.00	0.00	0.00
Gross Profit	0.00	0.00	0.00	0.00	0.00
Operating Expenses
Research & Development	46.18	54.81	113.32	90.62	34.47
Selling, General & Administrative	37.72	48.89	47.93	35.08	24.87
Operating Expenses	83.89	103.70	161.25	125.70	59.34
Operating Income	-83.89	-103.70	-161.25	-125.70	-59.34
Other Income/Expense
Interest Income	3.53	5.15	2.66	1.20	1.40
Interest Expense	0.00	0.00	0.00	0.00	0.00
Other Income/Expense	3.91	0.24	1.55	1.25	0.02
Income
Income Before Tax	-79.98	-98.79	-157.04	-125.75	-59.46
Income Tax Expense	0.00	88.61	6.20	0.00	0.00
Net Income	-79.98	-98.79	-157.04	-125.75	-59.46
Net Income - Continuous Operations	-79.98	-98.79	-157.04	-125.75	0.00
Net Income - Discontinued Operations	0.00	0.00	0.00	0.00	0.00
EBITDA	-83.89	-98.79	-161.25	-125.70	-59.33
EBIT	-79.93	-98.79	-161.25	-125.70	-59.34
Depreciation & Amortization	0.00	0.00	0.00	0.00	0.00
Earnings Per Share
Basic EPS	-3.00	-3.00	-5.00	-7.00	-4.00
Diluted EPS	-3.00	-3.00	-5.00	-7.00	-4.00
Basic Shares Outstanding	30.16	30.10	29.63	17.55	15.59
Diluted Shares Outstanding	30.16	30.10	29.63	17.55	15.59